Reimagining Global Oncology Clinical Trials for the Postpandemic Era: A Call to Arms
暂无分享,去创建一个
R. Plummer | J. Dancey | G. Curigliano | G. Bhattacharyya | J. García-Foncillas | G. Schiavon | M. Olivo | C. Twelves | A. Awada | K. Saini | M. Saini | K. Punie | V. Moreno | J. Cortés | Ø. Rekdal | J. De Castro | P. Aftimos | Lynda Chin | Marco Romano | J. Fredriksson | B. de las Heras | Kenneth Morrison | C. Orbegoso | Ernesto Rogata | Richie Pfeiffer | Steven Anderson | Manuela Leone | J. de Castro | K. Morrison | M. L. Saini
[1] E. Eisenhauer,et al. Covid-19 Pandemic-An Opportunity to Reduce and Eliminate Low-Value Practices in Oncology? , 2020, JAMA oncology.
[2] Jennifer L. Bell,et al. Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report , 2020, medRxiv.
[3] I. Moreno,et al. Increased vulnerability of clinical research units during the COVID‐19 crisis and their protection , 2020, Cancer.
[4] Dawn L. Hershman,et al. Association of the Coronavirus Disease 2019 (COVID-19) Outbreak With Enrollment in Cancer Clinical Trials , 2020, JAMA network open.
[5] G. Doherty,et al. Rethinking cancer clinical trials for COVID-19 and beyond , 2020, Nature Cancer.
[6] G. Elwyn,et al. Implications for Telehealth in a Postpandemic Future: Regulatory and Privacy Issues. , 2020, JAMA.
[7] Laura A. Levit,et al. Early Impact of COVID-19 on the Conduct of Oncology Clinical Trials and Long-Term Opportunities for Transformation: Findings From an American Society of Clinical Oncology Survey. , 2020, JCO oncology practice.
[8] C. Taniguchi,et al. Cancer Research after COVID-19: Where Do We Go from Here? , 2020, Cancer Cell.
[9] S. Mandrekar,et al. Understanding Verbosity: Funding Source and the Length of Consent Forms for Cancer Clinical Trials , 2020, Journal of Cancer Education.
[10] G. Bodoky,et al. ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy , 2020, ESMO Open.
[11] G. Curigliano,et al. Effect of the COVID-19 pandemic on cancer treatment and research , 2020, The Lancet Haematology.
[12] B. Waissengrin,et al. Breaking Bad News via Telemedicine: A New Challenge at Times of an Epidemic. , 2020, The oncologist.
[13] R. Platt,et al. Evidence from Pragmatic Trials during Routine Care - Slouching toward a Learning Health System. , 2020, The New England journal of medicine.
[14] E. Small,et al. Does the COVID-19 outbreak identify a broader need for an urgent transformation of cancer clinical trials research? , 2020, Contemporary Clinical Trials.
[15] R. Ohannessian,et al. Global Telemedicine Implementation and Integration Within Health Systems to Fight the COVID-19 Pandemic: A Call to Action , 2020, JMIR public health and surveillance.
[16] G. Melloni,et al. Artificial intelligence and radiomics enhance the positive predictive value of digital chest tomosynthesis for lung cancer detection within SOS clinical trial , 2020, European Radiology.
[17] J. Hollander,et al. Virtually Perfect? Telemedicine for Covid-19. , 2020, The New England journal of medicine.
[18] M. Mckee,et al. Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018. , 2020, JAMA.
[19] J. Zibert,et al. Virtual Clinical Trials: Perspectives in Dermatology , 2020, Dermatology.
[20] J. Gribben,et al. Reducing Bureaucracy in Clinical Research: A Call for Action , 2020, HemaSphere.
[21] M. Sydes,et al. Effective delivery of Complex Innovative Design (CID) cancer trials—A consensus statement , 2020, British Journal of Cancer.
[22] G. Jackson,et al. Artificial Intelligence Tool for Optimizing Eligibility Screening for Clinical Trials in a Large Community Cancer Center. , 2020, JCO clinical cancer informatics.
[23] C. Moskaluk,et al. Toward Improving Practices for Submission of Diagnostic Tissue Blocks for National Cancer Institute Clinical Trials. , 2019, American journal of clinical pathology.
[24] Marcus Woo,et al. An AI boost for clinical trials , 2019, Nature.
[25] Jennifer Elston-Lafata,et al. Challenges and opportunities using online portals to recruit diverse patients to behavioral trials , 2019, J. Am. Medical Informatics Assoc..
[26] Jonathan M Marron,et al. Ethical Framework for Including Research Biopsies in Oncology Clinical Trials: American Society of Clinical Oncology Research Statement. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] Christine Micheel,et al. Conceptual Framework to Support Clinical Trial Optimization and End-to-End Enrollment Workflow , 2019, JCO clinical cancer informatics.
[28] M. Knoll,et al. A Big World Made Small: Using Social Media to Optimize Patient Care. , 2019, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[29] Jens Rittscher,et al. The use of digital pathology and image analysis in clinical trials , 2019, The journal of pathology. Clinical research.
[30] Razelle Kurzrock,et al. Cancer research in the United States: A critical review of current status and proposal for alternative models , 2018, Cancer.
[31] Samuel L Volchenboum,et al. Use of Wearable, Mobile, and Sensor Technology in Cancer Clinical Trials. , 2018, JCO clinical cancer informatics.
[32] Ana Maria Lopez,et al. Telemedicine in Cancer Care. , 2018, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[33] Joanna Coast,et al. Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension , 2018, JAMA.
[34] Alan S Campbell,et al. Wearable non-invasive epidermal glucose sensors: A review. , 2018, Talanta.
[35] Tim Sprosen,et al. What are the main inefficiencies in trial conduct: a survey of UKCRC registered clinical trials units in the UK , 2018, Trials.
[36] Edward S. Kim,et al. Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] A. Awada,et al. How to emerge from the conservatism in clinical research methodology? , 2017, Current opinion in oncology.
[38] R. Pazdur,et al. Reevaluating Eligibility Criteria - Balancing Patient Protection and Participation in Oncology Trials. , 2017, The New England journal of medicine.
[39] Jay Evans,et al. Barriers to Scale of Digital Health Systems for Cancer Care and Control in Last-Mile Settings , 2017, Journal of global oncology.
[40] E. Namey,et al. Evidence-Based Strategies for Shortening Informed Consent Forms in Clinical Research , 2017, Journal of empirical research on human research ethics : JERHRE.
[41] M. Ratain,et al. Analysis of Impact of Post-Treatment Biopsies in Phase I Clinical Trials. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] R. Kurzrock,et al. An appraisal of drug development timelines in the Era of precision oncology , 2016, Oncotarget.
[43] John P. A. Ioannidis,et al. Why Most Clinical Research Is Not Useful , 2016, PLoS medicine.
[44] Leslie Lenert,et al. Teleconsent: A novel approach to obtain informed consent for research , 2016, Contemporary clinical trials communications.
[45] Olivier Chételat,et al. Clinical validation of LTMS-S: A wearable system for vital signs monitoring , 2015, 2015 37th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC).
[46] M. Romano,et al. Is the digital divide an obstacle to e-health? An analysis of the situation in Europe and in Italy. , 2015, Telemedicine journal and e-health : the official journal of the American Telemedicine Association.
[47] H. Kantarjian,et al. Impact of cancer research bureaucracy on innovation, costs, and patient care. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] G. Pond,et al. Data collection in cancer clinical trials: Too much of a good thing? , 2013, Clinical trials.
[49] Søren Overgaard,et al. Quality of Data Entry Using Single Entry, Double Entry and Automated Forms Processing–An Example Based on a Study of Patient-Reported Outcomes , 2012, PloS one.